FundedIQ
Biotechnology

Vicebio: Funding, Investors & Team (Sep 2026)

Vicebio is dedicated to using Molecular Clamp Technology to develop vaccines for upcoming respiratory viruses. The company specializes in producing new vaccines to protect against dangerous respiratory viral infections.

vicebio.com LinkedIn London, United Kingdom 1-10 employees
Biotechnology Medical B2B
Total raised
$100M
Rounds
1
Latest
Series B
Sep 2024

Vicebio has raised $100M across 1 funding round on record, the most recent a Series B of $100M announced in Sep 2024.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Vicebio Company Profile and Key Stats

Total funding raised
$100M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series B
$100M in Sep 2024
Employees
1-10
reported band
Headquarters
London, United Kingdom

Latest funding round on record: Sep 2024.

Vicebio Funding Rounds

Date
Round
Amount
Series B
$100M

Vicebio Founders and Leadership Team

Name
Role
Contact
Emmanuel Hanon
Founder

No contact details are on record for this team yet.

Vicebio Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
5,285
$4.0M
4,307
$30M

Vicebio's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Vicebio in Biotechnology and London

Companies Similar to Vicebio

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…

Series A $33.6M

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…

Undisclosed round $3.5M

Concert Bio helps businesses create optimal microbial communities.

Undisclosed round $130k

RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…

Series A $113M

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…

Undisclosed round $3.6M

Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…

Undisclosed round $3.0M

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

Series A $32.5M

IMU is a discovery engine mapping the immune system to advance precision medicine.

Series A $38.4M

Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…

Undisclosed round $5.4M

Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…

Undisclosed round

Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…

Pre-Seed $740k

Five is a biometric payment services company that offers thumb recognition technology for safe transactions.

Seed $6.0M

Vicebio Funding FAQs

What does Vicebio do?

Vicebio is dedicated to using Molecular Clamp Technology to develop vaccines for upcoming respiratory viruses. The company specializes in producing new vaccines to protect against dangerous respiratory viral infections.

How much funding has Vicebio raised?

Vicebio has raised $100M across 1 round on record. The most recent is a Series B of $100M announced in Sep 2024.

When did Vicebio last raise funding?

Vicebio's most recent funding round on record is a Series B of $100M, announced in Sep 2024.

Who founded Vicebio?

FundedIQ lists Emmanuel Hanon (Founder) at Vicebio.

Where is Vicebio headquartered?

Vicebio is based in London, England, United Kingdom.

How many employees does Vicebio have?

Vicebio is in the 1-10 employee band.

How does Vicebio's funding compare to other Biotechnology startups?

Vicebio's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Vicebio Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vicebio is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.